Invention Grant
US08741616B2 Regio- and enantioselective alkane hydroxylation with modified cytochrome P450
有权
修饰的细胞色素P450的区域和对映选择性烷烃羟基化
- Patent Title: Regio- and enantioselective alkane hydroxylation with modified cytochrome P450
- Patent Title (中): 修饰的细胞色素P450的区域和对映选择性烷烃羟基化
-
Application No.: US13673977Application Date: 2012-11-09
-
Publication No.: US08741616B2Publication Date: 2014-06-03
- Inventor: Frances H. Arnold , Matthew W. Peters , Peter Meinhold
- Applicant: The California Institute of Technology
- Applicant Address: US CA Pasadena
- Assignee: California Institute of Technology
- Current Assignee: California Institute of Technology
- Current Assignee Address: US CA Pasadena
- Agency: Gavrilovich, Dodd & Lindsey LLP
- Agent Joseph R. Baker, Jr.
- Main IPC: C12N9/02
- IPC: C12N9/02 ; C12N15/00 ; C12P7/00 ; C12P21/06 ; C12P21/04 ; C07H21/04

Abstract:
Cytochrome P450 BM-3 from Bacillus megaterium was engineered using a combination of directed evolution and site-directed mutagenesis to hydroxylate linear alkanes regio- and enantioselectively using atmospheric dioxygen as an oxidant. Mutant 9-10A-A328V hydroxylates octane primarily at the 2-positio to form S-2-octanol (40% ee). Another mutant, 1-12G, hydroxylates alkanes larger than hexane primarily at the 2-position, but forms R-2-alcohols (40-55% ee). These biocatalysts are highly active for alkane substrates and support thousands of product turnovers. These regio- and enantio-selectivities are retained in whole-cell biotransformations with E. coli, where the engineered P450s can be expressed at high levels and the expensive cofactor is supplied endogenously.
Public/Granted literature
- US20130273626A1 REGIO- AND ENANTIOSELECTIVE ALKANE HYDROXYLATION WITH MODIFIED CYTOCHROME P450 Public/Granted day:2013-10-17
Information query